MetaCap

Adagene (ADAG) vs Immunic (IMUX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunic (IMUX) has outperformed Adagene (ADAG) over the past year, gaining 1.9% versus a loss of 2.2%. Over five years, ADAG leads with a -79.7% price change compared with -91.9% for IMUX. Adagene is the larger company by market cap ($118.2 million vs $111.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADAG-2.22%IMUX+1.90%
+175%+70%-35%
Nov 21, 20251 yearNov 20, 2026
ADAG-81.97%IMUX-92.54%
+52%-25%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADAG versus IMUX key metrics
MetricADAGIMUX
Share price$1.76$6.99
Market cap$118.17M$111.01M
1-day change-12.44%-5.41%
YTD return-6.88%+30.90%
1-year return-2.22%+1.90%
5-year return-79.75%-91.88%
EPS (TTM)$-0.37$-3.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.67M—
Revenue growth (YoY)+7332.76%—
Net income (latest FY)$-17.61M$-97.17M
Operating margin-279.48%—
Net margin-229.56%—
52-week high$4.85$17.43
52-week low$1.27$5.06
Distance from 52-week high-63.71%-59.90%
Analyst consensusnonestrong_buy
Avg. price target upside+463.07%+508.73%
Average volume348.81K343.44K
Shares outstanding67.14M15.88M
Employees128100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Adagene

ADAG stock →

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

ADAG vs IMUX FAQ

Which is bigger, Adagene or Immunic?

Adagene (ADAG) is larger, with a market capitalization of $118.17M compared with $111.01M for Immunic (IMUX).

Which stock has performed better over the past year, ADAG or IMUX?

IMUX returned +1.90% over the past 12 months, compared with -2.22% for ADAG (price return, excluding dividends). Past performance does not predict future results.

Are Adagene and Immunic in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons